HOME >> MEDICINE >> NEWS
More than half of relapsed CLL patients respond to two biologics with chemotherapy

SAN DIEGO - The University of Texas M. D. Anderson Cancer Center offers these news items presented at the annual meeting of the American Society of Hematology (ASH).

Combining two biologic agents with chemotherapy forms a potent drug regimen that is showing promise in treating patients who have relapsed with the most common kind of leukemia, chronic lymphocytic leukemia (CLL), researchers from The University of Texas M. D. Anderson Cancer Center report at the annual meeting of the American Society of Hematology (ASH).

The researchers combined two different monoclonal antibodies, alemtuzumab (Campath-1H) and rituximab (Rituxan) with the chemotherapy drugs cyclophosphamide and fludarabine. The combination is referred to as CFAR. Of 31 currently evaluable patients, 7 (23 percent) achieved complete remission, meaning no evidence of CLL remains, and the amount of leukemia in 11 patients (35 percent) has been reduced by at least half, says William Wierda, M.D., Ph.D., assistant professor of medicine in the Department of Leukemia.

"An overall response rate so far of 55 percent is very encouraging in this heavily pretreated population of patients that had limited treatment options," he says.

This study follows one reported by Wierda at last year's ASH meeting in which 143 less heavily pretreated patients were treated with rituximab, cyclophosphamide and fludarabine. This combination produced a response rate of 72 percent, of which 28 percent of patients achieved complete response remission. This complete remission rate was much higher than groups treated with either chemotherapy alone, or in combination.

Wierda and his group thought about adding alemtuzumab to the combination because of the synergistic activity of FCR and report that fludarabine combined with alemtuzumab had activity in patients that were resistant to both these agents. Alemtuzumab targets CD52, a protein expressed on the surface of leukemia cells. Rituximab, approved
'"/>

Contact: Nancy Jensen
nwjensen@mdanderson.org
713-794-1584
University of Texas M. D. Anderson Cancer Center
6-Dec-2004


Page: 1 2

Related medicine news :

1. Study finds Velcade major improvement over standard therapy for relapsed multiple myeloma patients
2. New guidelines for drug studies for relapsed prostate cancer patients
3. Hormonal treatment improves survival in high-risk prostate cancer patients
4. Study finds that coordinating care of chronically ill patients does not increase liability
5. Mouse model reveals potential way to reduce cardiac deaths in kidney patients
6. Optical technique identifies vulnerable plaques in cardiac patients
7. NHS target driven culture is failing patients
8. Cardiac deaths peak in sleep hours for patients with sleep apnea
9. Chronic fatigue patients show lower response to placebos
10. Depression linked to insomnia in HIV patients
11. Disfigured patients may be forced to forego surgery

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/1/2020)... (PRWEB) , ... September 01, 2020 , ... ... it has completed $3 million convertible note financing, which will be used to ... With the funds from this financing, the company will continue to expand its ...
(Date:8/31/2020)... PITTSBURGH (PRWEB) , ... August 31, 2020 , ... ... Allegheny Health Network (AHN), are joining biomedical engineers from Carnegie Mellon University (CMU) ... alternative for cardiac patients who have undergone open heart surgery. , The AGH/CMU ...
(Date:8/31/2020)... ... 31, 2020 , ... Want to get moving, break up your routine, and ... is thrilled to launch its fourth annual STEPtember campaign in the United States to ... everyone wherever they are at this moment — encouraging people to move in the ...
(Date:8/31/2020)... ... ... pandemic and topsy-turvy economic outlook continues to put financial strain on many of us, so ... fat from our monthly expenses and put more into savings, if possible. , “That’s a ... financial safety net in place in case something were to happen to you,” says Lee ...
(Date:8/31/2020)... ... August 31, 2020 , ... Bonde ... for patients with advanced heart failure, today announced that the company has been ... of $555,358 from the National Heart, Lung, and Blood Institute of the National ...
Breaking Medicine News(10 mins):
(Date:9/1/2020)... ... ... September is National Ovarian Cancer Awareness Month. Ovarian cancer is the ... the female reproductive system. The American Cancer Society estimates that in 2020, about ... from this disease. Throughout the month of September, Women’s Excellence aims to increase ...
(Date:8/31/2020)... ... August 31, 2020 , ... Cloudticity announced ... named Cloudticity a Gold winner in the 15th Annual 2020 Network PG’s IT ... o ns from Network Products Guide honoring achievements of world’s best in ...
(Date:8/27/2020)... ... August 27, 2020 , ... ... today announced the successful completion of their 2020 System and Organizational Controls (SOC) ... HITRUST® interim assessment and MARS-E compliance assessment. These achievements reflect their long-standing commitment ...
Breaking Medicine Technology:
Cached News: